Biotie Therapies (OMXH: BTH1V) said this morning that US National Institute on Drug Abuse (NIDA) will conduct a phase 2b clinical study on Biotie's dopamine β-hydroxylase inhibitor Nepicastat (SYN-117) in Cocaine Dependence. Under the Collaborative Research and Development Agreement with NIDA, the parties will investigate the drug candidate in 180 treatment-seeking cocaine-dependent subjects for the treatment of drug dependance.
Biotie got the rights to the compound when it merged with Synosia Therapeutics AG in the beginning of the year. Previously a phase 2a study with Nepicastat in cocaine addicts who did not feel they needed treatment was done and the conclusion from that was that the drug is safe and well tolerated (also in combination with cocaine) and that it lessens the pleasure that subjects feel when taking cocaine. Biotie's stock is up 7% in today's trading. The stock has a near-term catalyst with the expected MAA filing of Nalmefene for alcohol dependance.
No comments:
Post a Comment